US Patent

US8022279 — Liposomal formulations of anthracycline agents and cytidine analogs

Method of Use · Assigned to Celator Pharmaceuticals Inc · Expires 2027-09-14 · 1y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects liposomal formulations that combine an anthracycline agent with a cytidine analog, such as cytarabine, for sustained drug release.

USPTO Abstract

Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3147 — Cytarabine

Patent Metadata

Patent number
US8022279
Jurisdiction
US
Classification
Method of Use
Expires
2027-09-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Celator Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.